Podcast Episodes
Back to SearchHow Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
Episode 189
Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer.
Leyden Labs is pione…
6 months, 3 weeks ago
How to optimize your biotech company for partnering, licensing, and business success
Episode 188
Today, we welcome Janita Good, a Partner at Fieldfisher with nearly two decades of experience advising top organizations in pharmaceuticals, biotechn…
7 months ago
Reversing tumor immunosuppression with next-gen GPCR modulation
Episode 187
Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy a…
7 months, 1 week ago
Misinformation is a public health crisis - here's how to fix it
Episode 186
Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longev…
7 months, 2 weeks ago
Accelerating rare disease cures with ASOs, gene editing, and AI
Episode 185
Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the Un…
7 months, 3 weeks ago
Using AI to crack undruggable drug targets
Episode 184
As we mark the International Day of Women and Girls in Science, we welcome Avital Sharir-Ivry, Co-Founder and Chief Scientific Officer of ProPhet, an…
8 months ago
How Eli Lilly's biotech collaboration model is rewriting early-stage innovation
Episode 183
Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thom…
8 months, 1 week ago
Building a smart oncology pipeline with Cumulus Oncology
Episode 182
Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh.
With over 25 years of expertise in oncology d…
8 months, 2 weeks ago
Top 5 trends that will drive biopharma in the next decade with Tim Opler
Episode 181
Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding T…
8 months, 3 weeks ago
Labiotech's 15 biopharma companies to watch in 2026
Episode 180
Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules …
9 months ago